# The ups and downs of paclitaxel-coated balloons and paclitaxel eluting stents: do the conclusions of SWEDEPAD 2 change our practice? Should we be concerned about mortality (again)?

## TL;DR

This paper discusses the ongoing debate about the safety and effectiveness of paclitaxel-coated devices in treating peripheral arterial disease.

## Contribution

The paper evaluates the implications of the SWEDEPAD 1 and 2 trials on current clinical practices regarding paclitaxel-coated devices.

## Key findings

- SWEDEPAD 1 and 2 trials have raised concerns about the potential link between paclitaxel-coated devices and mortality.
- The trials have rekindled discussions about the efficacy and safety of these devices in peripheral arterial disease.
- The paper questions whether these findings will change clinical practice.

## Abstract

The use of paclitaxel-coated devices (PCDs) in peripheral arterial disease continues to generate interest and controversy. The PCD journey to date has been a story of highs and lows. The recently published SWEDEPAD 1 and 2 trials have rekindled discussion regarding efficacy and a potential link to mortality.